Users online: 2538    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 9
First page : ( 4119) Last page : ( 4125)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00757.6

Formulation Development of Metformin HCl and Repaglinide Bilayer Tablets: A Novel approach to improve Therapeutic Efficacy

Kumari M. Sujatha*, Babu M. Kishore, Rajesh K., Jyothsna G., Reddy G. Jeevan

Department of Pharmaceutics, Sri Siddhartha Pharmacy College, Nuzvid, Andhra Pradesh-521201, India

*Corresponding Author E-mail: Sujatha.pharmacy@gmail.com

Online published on 20 December, 2018.


Many antidiabetic drugs including sulfonyl ureas, Rosiglitazone and even Insulin have been suspected to have adverse cardiovascular effects. Lactic acidosis is the feared adverse effect of the biguanide drugs with high doses. We suggest that the mean plasma concentrations of Metformin over a dosage interval be maintained below 2.5 mg/L in order to minimize the development of this adverse effect. The present research work was an attempt to design a novel formulation to improve the oral therapeutic efficacy with optimal control of plasma drug level which contains two antidiabetic drugs Metformin HCl and Repaglinide. Bilayer tablet formulation has been developed consisting of two drug containing layers which comprises Metformin sustained mucoadhesive release layer and an immediate release layer of Repaglinide was optimised separately and constituted in bilayer tablet, a common analytical method for quantitative combined drug estimation was employed and evaluated by HPLC.



Sustained release, Immediate release, Metformin HCl, Repaglinide, Mucoadhesive formulation.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
642,886,713 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.